Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A T den Boer

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
American Journal of Medical Genetics|December 18, 1996
Angelman syndrome in adulthoodL A Laan, A T den Boer, R C Hennekam, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 24, 2000
The role of CD40 in peripheral T cell tolerance and immunityL Diehl, A T Den Boer, E I van der Voort, et al.
American Journal of Medical Genetics|March 21, 1998
Angelman syndrome without detectable chromosome 15q11-13 anomaly: clinical study of familial and isolated casesL A Laan, D J Halley, A T den Boer, et al.
Nature Medicine|July 8, 1999
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacyL Diehl, A T den Boer, S P Schoenberger, et al.
Cancer Research|October 28, 1999
Successful immunotherapy of an intraocular tumor in miceL R Schurmans, A T den Boer, L Diehl, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus toleranceA T den Boer, L Diehl, G J van Mierlo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2001
Rejection of intraocular tumors by CD4(+) T cells without induction of phthisisL R Schurmans, L Diehl, A T den Boer, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
American Journal of Medical Genetics|December 18, 1996
Angelman syndrome in adulthoodL A Laan, A T den Boer, R C Hennekam, et al.
Journal of Molecular Medicine (Berlin, Germany)|October 24, 2000
The role of CD40 in peripheral T cell tolerance and immunityL Diehl, A T Den Boer, E I van der Voort, et al.
American Journal of Medical Genetics|March 21, 1998
Angelman syndrome without detectable chromosome 15q11-13 anomaly: clinical study of familial and isolated casesL A Laan, D J Halley, A T den Boer, et al.
Nature Medicine|July 8, 1999
CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacyL Diehl, A T den Boer, S P Schoenberger, et al.
Cancer Research|October 28, 1999
Successful immunotherapy of an intraocular tumor in miceL R Schurmans, A T den Boer, L Diehl, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 18, 2001
Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus toleranceA T den Boer, L Diehl, G J van Mierlo, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 8, 2001
Rejection of intraocular tumors by CD4(+) T cells without induction of phthisisL R Schurmans, L Diehl, A T den Boer, et al.
Pageof 1